Conexeu Sciences Inc. (CNXU)
Market Closed
2 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
10. 86
+0.6
+5.848%
After Hours
$
+0.86 +7.919% 11. 72
228.46M Market Cap
- P/E Ratio
- Div Yield
70,196 Volume
- Eps
$ 10.26
Previous Close Want to track CNXU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission
Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance by Q1 2027, potentially accelerating market entry to late 2027 and minimizing investor dilution. Current valuation (~$13.20/share) exceeds risk-adjusted fair value ($10.71), but premium is justified by pipeline breadth and upside if regulatory milestones are met.
Seekingalpha | 1 week ago
